AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportRecursion Pharmaceuticals vs Schrödinger
VS
Recursion Pharmaceuticals
Enterprise
Schrödinger
Enterprise
Verdict by Category
Detailed category analysis is not available for this comparison.
Feature & Spec Matrix
Detailed Comparison25 Criteria
Complete side-by-side breakdown of specifications, capabilities, and feature parity
Swipe horizontally to compare features
Feature / Spec
Pricing Model
EnterpriseAI-enabled drug discovery and mapping (Recursion OS) — Custom biopharma enterprise partnership agreements only
EnterprisePhysics-based molecular modeling & drug discovery suite — Academic site licenses & commercial enterprise quotes on sales consultation
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
No self-serve access — enterprise pharma collaborations and data licensing via partnership team
Academic licensing available at reduced rates; commercial pricing via sales team
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Major pharma companies and researchers needing AI-powered biology mapping, target discovery, and drug candidate generation at industrial scale through the Recursion OS platform
Pharmaceutical scientists and computational chemists needing physics-based molecular simulation for drug discovery, lead optimization, and ADMET prediction
Enterprise & Scalability
Difference
NASDAQ listed (RXRX), $500M+ in pharma partnership milestones earned, enterprise collaboration agreements with Roche/Genentech and Sanofi, automated biology and chemistry labs at industrial scale in Salt Lake City and Oxford, and data licensing for external researchers
NASDAQ listed (SDGR), enterprise software licensing with volume pricing, cloud-hosted subscriptions, strategic research collaborations with BMS, Sanofi, and Takeda, dedicated scientific support teams, and academic/government licensing programs
Core Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Recursion OS — AI-native end-to-end drug discovery platform integrating biology, chemistry, and clinical development
Supported
Supported
Industrial-scale automated labs in Salt Lake City and Oxford generating proprietary multimodal data
Difference
Recursion Pharmaceuticals Advantage
Not listed
REC-4881 for FAP — 53% polyp reduction in Phase 2, FDA registration discussions begun 2026
Difference
Recursion Pharmaceuticals Advantage
Not listed
REC-1245 (RBM39 degrader) in Phase 1/2 DAHLIA study for solid tumors
Difference
Recursion Pharmaceuticals Advantage
Not listed
REC-4539 (LSD1 inhibitor) — first patient dosed in Phase 1 ENLYGHT study 2026
Difference
Recursion Pharmaceuticals Advantage
Not listed
Sanofi partnership — $134M earned to date across 5 milestones
Difference
Recursion Pharmaceuticals Advantage
Not listed
Roche/Genentech Phenomaps — 1 trillion neuronal cells for neuroscience target discovery
Difference
Recursion Pharmaceuticals Advantage
Not listed
$500M+ in cumulative pharma partnership milestones earned to date
Difference
Recursion Pharmaceuticals Advantage
Not listed
Recursion Data — phenomics and biology maps licensed to external researchers and pharma
Difference
Recursion Pharmaceuticals Advantage
Not listed
NASDAQ: RXRX — founded 2013; $74.7M revenue in 2025; acquired Exscientia in 2024
Supported
Supported
Bunsen AI co-scientist (July 2026) for hypothesis generation, experiment design, and molecular insight
Difference
Not listed
Schrödinger Advantage
FEP+ for industry-leading binding affinity prediction in lead optimization
Difference
Not listed
Schrödinger Advantage
Structure-based drug design, ADMET prediction, and quantum chemistry in one platform
Difference
Not listed
Schrödinger Advantage
Cloud-hosted software subscriptions with 10-15% ACV growth target for 2026
Difference
Not listed
Schrödinger Advantage
Drug discovery pipeline with BMS, Sanofi, and Takeda — FY26 guidance raised to $65-75M
Difference
Not listed
Schrödinger Advantage
Materials science applications: battery design, semiconductors, and specialty chemicals
Difference
Not listed
Schrödinger Advantage
500+ enterprise customers including top 20 global pharma companies
Difference
Not listed
Schrödinger Advantage
Founded 1990 by Professor Richard Friesner — 34+ years of computational chemistry leadership
Difference
Not listed
Schrödinger Advantage
Recursion Pharmaceuticals Pros & Cons
Pros
- $500M+ in pharma partnership milestones — most validated AI drug platform by commercial revenue
- Recursion OS is the most vertically integrated AI drug discovery system — biology to clinic in one platform
- Industrial-scale automated labs generate data no other company can replicate
- Phase 2 FAP clinical proof of concept — 53% polyp reduction — FDA registration discussions began
- Roche/Genentech and Sanofi as partners — two of the world's top 5 pharma companies
- Exscientia acquisition in 2024 added cutting-edge small molecule AI design capabilities
- Cash runway guided into early 2028 — disciplined capital allocation
Cons
- Stock (RXRX) is below $5 — significant market skepticism on timeline to commercial drugs
- Operating cash burn of ~$390M in 2026 — needs continued capital or milestone payments
- Acquired Exscientia in 2024 — integration complexity and added operational overhead
- No approved drugs yet — clinical proof of concept still early stage
- Proprietary platform requires industrial-scale automation infrastructure that can't be self-built
Schrödinger Pros & Cons
Pros
- 34+ years of computational chemistry leadership — most trusted physics-based platform in pharma
- Bunsen AI co-scientist launched July 2026 — BMS immediately deployed it
- FEP+ delivers industry-leading accuracy in binding affinity prediction
- NASDAQ SDGR — $255.87M revenue in 2025, 23% growth, turning profitable in Q2 2026
- 500+ pharma enterprise customers including BMS, Sanofi, Takeda, Pfizer, and Eli Lilly
- Materials science applications extend reach to battery, semiconductor, and chemical sectors
- Cloud-hosted subscriptions eliminate on-premise infrastructure burden
Cons
- Software is expensive — enterprise pricing puts it out of reach for smaller labs
- Stock (SDGR) has been under pressure — market cap ~$1B despite strong platform
- Drug discovery segment revenue is milestone-dependent and lumpy
- Platform learning curve is steep without computational chemistry background
- Competition from newer, purely AI-native platforms is intensifying
Head-to-Head Battle Cards
Popular Comparisons
Direct feature matrices, pricing breakdowns, and real-world benchmark duels
AI Healthcare ToolsCompare
AI Healthcare ToolsCompare
AI Healthcare ToolsCompare
AI Research Synthesis & Personal Knowledge ManagementCompare